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1. Introduction 
What is marijuana? Marijuana, also known as Cannabis, is defined as any preparation of the 
Cannabis sativa plant used to exploit psychoactive effects whether it is recreational or 
medicinal. According to the 2004 World Drug Report, 3.7% of the population 15-64 years of 
age consumed marijuana from 2001-2003 (World Drug Report, 2004). The use of marijuana is 
associated with numerous pharmacological effects; most, but not all may attributed to 
tetrahydrocannabinol (THC). The combination of THC and other compounds from Cannabis 
sativa may all exhibit specific pharmacological effects. These isolates from Cannabis are 
known as cannabinoids (ElSohly, 2010).  
Cannabinoids are a chemical class of C21 terpenophenolic compounds that represent a group 
of compounds found in Cannabis sativa (Mechoulam & Gaoni, 1967). Phytocannabinoids are 
the naturally occurring cannabinoids from Cannabis sp (Pate, 1999). It is now known that at 
least 85 cannabinoids have been derived from Cannabis sativa (El-Alfy et al., 2010). It is also 
known that some of these compounds are of medical importance in today’s society. 
In order to gain a better understanding of the pharmacological effects of the 
phytocannabinoids, human and rodent receptors are used to evaluate binding affinity of 
these compounds to two cannabinoid receptors that have been reported in literature, CB1 
and CB2. CB1 receptors are located mainly in the brain, while CB2 receptors are primarily  
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peripheral and found on mature B cells and macrophages within the tonsils and spleen  
(Raymon & Walls, 2010). When activated, the CB1 receptors exhibit the psychoactive effects 
caused by Cannabis use. Since CB1 receptors are not present in the medulla oblongata, part of 
the brain stem responsible for respiratory and cardiovascular functions, there is not a risk of 
overdose resulting in respiratory depression or cardiovascular failure that may be seen with 
abuse of other drugs, such as the opioids. CB2 receptors are said to be responsible for anti-
inflammatory effects. 
2. Cannabinoid receptor function 
Cannabinoid receptors are G-protein coupled receptors (Figure 1), which are a large 
family of seven member transmembrane receptors that act in a second messenger fashion. 
When cannabinoid receptors are activated, they inhibit the enzyme adenylate cyclase. 
Adenylate cyclase is responsible for breaking ATP to form cyclic AMP (cAMP). When a 
ligand binds to the extracellular surface of cannabinoid receptors, it causes a 
conformational change of the receptor. This change activates the second messenger by 
exchanging guanosine diphosphate (GDP) for guanosine triphosphate (GTP). Then, the G-
protein’s alpha subunit separates from the beta/gamma subunit to cause intracellular 
proteins to function properly. In CB1 and CB2 receptors, cAMP acts as the second 
messenger. When these receptors are activated, cAMP levels decrease within the cell. 
Therefore, the result of activating cannabinoid receptors leads to a decrease in cAMP 
levels, and in turn leads to an inhibition of function.  
 
Fig. 1. Example of a G-Protein Coupled Receptor. 
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3. Endocannabinoids 
Endogenous cannabinoids, or endocannabinoids, are substances produced in the body that 
activate the cannabinoid receptors. Generally, neurotransmitters are released presynaptically 
and activate the receptors on a postsynaptic cell. However, unlike most neurotransmitters, the 
endocannabinoids work in a reverse fashion. Endocannabinoids use retrograde signaling to 
achieve cannabinoid receptor activation. This means that the ligands are being produced 
postsynaptically, but acting presynaptically (Lambert, 2009). Another critical point in 
understanding the function of the endocannabinoids is that the endocannabinoid system can 
produce endocannabinoids “on demand” in response to an increase in intracellular calcium 
levels (Sugiura et al., 2006).  
Shortly after the cloning of the cannabinoid receptors, researchers began searching for 
endogenous ligands that activate these receptors. The first endocannabinoid discovered was 
anandamide (Figure 2) in 1992 (Devane et al., 1992). Several years after the discovery of 
anandamide the second endogenous ligand, 2-arachadonoyl-glycerol (2-AG, Figure 3), was 
discovered (Sugiura et al., 2006). Anandamide and 2-AG act as a partial agonist and full 
agonist, respectively, at the CB1 and CB2 receptors. Although the structure of anandamide 
differs significantly from THC, both of these ligands have similar pharmacological profiles 
(Grotenhermen, 2002). Understanding the mechanism of how cannabinoids produce their 
effects is in part because of the discovery of the endocannabinoid system.  
 
Fig. 2. Chemical structure of anandamide. 
Although the physiological roles of the endocannabinoids are not fully defined, several 
pharmacological functions have been described. Studies suggest that these endogenous 
ligands may aid in pain relief, enhancement of appetite, blood pressure lowering during 
shock, embryonic development, and blocking of working memory (ElSohly, 2010).  
 
Fig. 3. Chemical structure of 2-AG. 
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4. Phytocannabinoids 
The first cannabinoid identified was cannabigerol, and its precursor cannabigeric acid was 
shown to be the cannabinoid formed in the plant as well as endogenously (Yamauchi, 1975). 
Today, the most discussed phytocannabinoid is delta-9-tetrahydrocannabinol. In 1964, 
Gaoni and Mechoulam isolated and elucidated the chemical structure of THC from the 
leaves of Cannabis sativa (Mechoulam & Gaoni, 1964). THC is pharmacologically and 
toxicologically the best studied constituent of Cannabis, responsible for most of the 
psychoactive effects of natural Cannabis preparations (Grotenhermen, 2002). THC and 
cannabidiol (CBD) are the two most common naturally occurring cannabinoids.  
As mentioned earlier, THC (Figure 4) is the main component of Cannabis responsible for the 
psychoactive effects. Other than Cannabis being abused to achieve a state of euphoria, it is 
now being used medicinally to aid in acquired immunodeficiency syndrome (AIDS) patients 
with wasting syndrome and for pain management, nausea, and vomiting associated with 
patients receiving cancer chemotherapy. Since THC is responsible for the psychoactive 
effects of Cannabis, people have learned how to genetically increase the concentration of 
THC within each plant to produce a stronger “high.” Since 1980, the concentration of THC 
within marijuana has increased from less than 1.5% to approximately 20% (ElSohly et al., 
2000). THC acts a partial agonist at the CB1 and CB2 receptors, but functions via interaction 
with the CB1 receptor.  
 
Fig. 4. Chemical structure of delta-9-THC. 
The second major constituent of Cannabis, cannabidiol (CBD, Figure 5), is responsible for the 
anti-inflammatory effects due to its interactions with the human CB2 receptor. CBD was first 
isolated in 1940 (Adams et al., 1940); however, it was not until 1963 that Mechoulam and 
Shvo elucidated its correct structure (Mechoulam & Shvo, 1963). At the human CB2 receptor, 
CBD’s mechanism of action shows inverse agonism activity (Pertwee et al., 2007). In 1995, 
Benet and colleagues show that cannabidiol is not only responsible for anti-inflammatory 
effects, but may also aid in reducing unpleasant side effects from THC, including reduced 
anxiety (Benet et al., 1995). They found that CBD inhibits cytochrome P450 3A11, which 
causes THC to change into its more potent metabolite 11-hydroxy-THC (Gallily et al., 
2002). 
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Fig. 5. Chemical structure of cannabidiol. 
Tetrahydrocannabinol and cannabidiol are the two most discussed phytocannabinoids, but 
not the only ones known. ElSohly and co-investigators have divided the phytocannabinoids 
into ten subclasses: 1) Cannabigerol type – propyl side chains and monomethyl ether 
derivatives 2) Cannabichromene type – analogs present in the C-5 position 3) Cannabidiol 
type – analogs varying from C-1 to C-5 positions 4) Delta-9-tetrahydrocannabinol type – 
double bond in the C-9 position; responsible for psychoactive effects 5) Delta-8-
tetrahydrocannabinol type – double bond in the C-8 position; thermodynamically more 
stable than delta-9-THC , however, 20% less active 6) Cannabicyclol type – five atom ring 
and C-1 bridge 7) Cannabielsoin type – artifacts formed from CBD 8) Cannabinol and 
Cannabinodiol types – A ring aromatization 9) Cannabitriol type – additional hydroxyl 
substitution 10) Miscellaneous types – ex: furano ring, carbonyl function, tetrahydroxy 
substitution (ElSohly, 2010).  
Another phytocannabinoid that shows a significant amount of importance is cannabinol 
(CBN, Figure 6); it is a metabolite of tetrahydrocannabinol. It was the first cannabinoid 
identified from Cannabis sativa. (Wood et al., 1896). Along with THC, cannabinol is also a 
psychoactive component of Cannabis due to its interaction with CB1 receptors. Compared to 
THC, it acts a weak agonist at both the CB1 and CB2 receptors.  
 
Fig. 6. Chemical structure of cannabinol.  
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Extracts that have been isolated from marijuana may be tested to see if they have affinity for 
each of the CB1- or CB2- type receptors. THC remains the best phytocannabinoid in terms of 
affinity for the cannabinoid receptors with a binding Ki of 14nM (Figure 7). Most of the 
compounds isolated from Cannabis show a sufficient amount of binding activity at both of 
the cannabinoid receptors. However, not all compounds isolated show interactions with 
either CB1 or CB2. For instance, even though cannabidiol is a major constituent of Cannabis 
and shows pharmacological effects, it has little or no activity for CB1 or CB2 receptors 
(Mechoulam & Rodriguez, 2007). To determine binding affinity and functional activity, in 
vitro assays are performed.  
 
Fig. 7. Binding affinity of delta-9-THC at Cannabinoid Receptor 1 and Cannabinoid Receptor 
2. 
5. In vitro bioassays 
In order to have success with in vitro assays, cultured cells containing the specific receptors 
must be developed. At the University of Mississippi HEK293 cells have been transfected with 
full length human CB1 and human CB2 DNA via electroporation. Once “shocked,” the cells 
open and accept the human CB1 and CB2 cDNA with a linked specific antibiotic resistant 
plasmid. Since not all cells will receive the DNA, a selection process using the specific 
antibiotic is added to the cultured cells in order to kill off cells without the cDNA. After an 
allotted time period for growth, a single cell is selected and clonal colonies are grown in cell 
culture. The replication of a single cell containing either CB1 or CB2 DNA allows researchers to 
guarantee the over expression of cannabinoid receptors on the cell membrane. With this, mass 
subculture followed by “scraping” of the cells leads to the membrane with the receptors. Once 
the protein concentration is determined this membrane may be used for in vitro assays.  
Phytocannabinoids may be tested for their binding affinity toward each of the cannabinoid 
receptors. A competitive binding assay is done to determine the binding affinity of each 
compound. The competition is between the chosen phytocannabinoid and a labeled ligand, 
such as 3H- CP-55, 940. It is known that the labeled ligand will tightly bind to each of the 
cannabinoid receptors; therefore, if a test compound shows affinity for the receptors, the 
www.intechopen.com
 
Phytocannabinoids 279 
amount of labeled ligand bound to the receptor will be low resulting in high binding affinity 
of the test compound. A compound showing strong binding affinity for either of the 
cannabinoid receptors, warrants testing to determine the functional activity.  
A functional assay determines whether the compound is acting as an agonist, antagonist, or 
inverse agonist. As opposed to the binding assay, an in vitro functional assay is not based 
upon competitive binding, but rather “tracking” the amounts of guanosine triphosphate 
(GTP). When the membrane is not stimulated, there is a pool of guanosine diphosphate 
(GDP) associated with it. Upon stimulation, this pool of GDP is converted into GTP. To 
monitor this response, 35S labeled GTP is added to the assay to bind to the receptors. 
Therefore, an increase in GTP is directly proportional to stimulation of the receptor by 
labeled ligand. An agonist compound is indicated by an increase in GTP. Delta-9-THC has a 
functional Ki of approximately 300nM, which means it is acting as a partial agonist, yet is 
still responsible for the psychoactive effects associated with Cannabis (Figure 8). To detect an 
antagonist, the compound must be tested in the presence of a known agonist at that specific 
receptor. The antagonist blocks the ability of the agonist to fully stimulate the receptor, thus 
resulting in a right shift of the agonist EC50. 
 
Fig. 8. Functional assay activity of delta-9-THC at Cannabinoid Receptor 1 and Cannabinoid 
Receptor 2. 
6. In Vivo bioassays 
Cannabinoids that show promising activity in the functional assay, whether acting as an 
agonist or antagonist, may be tested in vivo using the tetrad assay in mice. In the late 1980s, 
Little and his colleagues began testing rodents treated with cannabinoids in this tetrad assay. 
The term tetrad describes a series of four different tests to help evaluate the biological effects of 
a compound: 1) Locomotor activity 2) Catalepsy 3) Hypothermia and 4) Analgesia. The 
locomotor activity test allows a researcher to determine if the rodent is acting “lazy.” The 
rodent is placed in a box with perpendicular gridlines, which are beams of light. The test 
determines the amount of times the beams are broken in an allotted time period, an increase in 
the number of times broken correlates with a decrease in locomotor activity. To determine if 
the drug causes cataleptic effects, a rodent is placed on a bar elevated off the ground surface. If 
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the rodent remains immobile, it is considered cataleptic. Hypothermia, also know as a rectal 
temperature assay, is simply a measure of the rodents rectal temperature after the drug has 
been administered. For the last part of the tetrad assay, there are two different methods of 
testing for analgesic effects. One method is the hot plate (Figure 9) assay. In this assay, a rodent 
is placed upon a hot plate and the time it takes for the rodent to react, usually a small jump, is 
recorded. The second method is known as the tail-flick assay. In this assay, the rodent is 
immobilized and a high temperature beam of light is sporadically placed on the tail. If the 
rodent feels pain, it will move its tail either left or right (Little, 1988). 
 
Fig. 9. Analgesic portion of tetrad assay: hot plate test. 
7. Medicinal uses of marijuana  
According the United Nations, Cannabis “is the most widely used illicit substance in the 
world” (World Drug Report, 2010). There are people who use Cannabis medicinally, and 
there are others who abuse Cannabis in order get “high,” or obtain a state of euphoria. Those 
who use marijuana regularly for medicinal purposes use strict, smaller amounts to control 
the strength and duration of the “high.” However, those who abuse marijuana attempt to 
smoke or ingest as much as necessary to achieve their own personal state of euphoria. This 
abuse negatively affects the people who do need Cannabis to help with side effects of 
chemotherapy and AIDS. Cannabis is not only used to help those suffering from cancer 
chemotherapy and AIDS, but it also lowers intraocular eye pressure for those with 
glaucoma, acts a pain reliever, and more recently has been found to help with symptoms of 
multiple sclerosis and depression. Therefore, researchers are attempting to formulate a 
synthetic cannabinoid that resembles the compounds isolated from Cannabis, but do not 
exploit psychotropic properties.  
The goal of research in this area is to synthesize a cannabinoid-like compound that warrants 
a high affinity for either CB1 or CB2 receptors, or both, and can help patients without causing 
some of the unwanted side effects of marijuana, such as the psychotropic effects associated 
with CB1. With this said, studies show that Cannabis users have fewer psychological side 
effects than those users administering synthetic THC. There are two synthetic cannabinoid 
products available on the market in the United States, Nabilone and Dronabinol (Figure 10). 
Some of these side effects from synthetic cannabinoids include dysphoria, 
depersonalization, anxiety, and paranoia (Grinsponn & Bakalar, 1997). As previously 
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mentioned, CBD has shown to reduce anxiety and other unpleasant side effects caused by 
ingestion of pure THC (Zuardi et al., 1982). The preference of whole Cannabis over synthetic 
formulations of THC is due to the lack of extra side effects associated with the whole 
Cannabis. This opens the door for scientists to study what is actually causing all of the side 
effects associated with synthetic THC. This also shows that some of the compounds 
associated with Cannabis sativa may be working synergistically to alleviate unwanted effects 
from THC when used alone (McPartland & Russo, 2001). So, the ultimate goal in 
cannabinoid drug development would be to mimic the non-psychotropic effects associated 
with CB1, mimic the beneficial effects associated with CB2, and not deal with the negative 
side effects associated with marijuana or synthetic THC. 
  
Fig. 10. Chemical structures of Nabilone (left) and Dronabinol (right). 
8. Phytocannabinoids and depression 
Depression may be described as a mood disorder associated with feeling down, sad, angry, 
or lost that interferes with everyday life. The most commonly associated drug categories for 
the treatment of depression include monoamine oxidase inhibitors (MAOIs), tricyclic 
antidepressants (TCAs), selective-serotonin reuptake inhibitors (SSRIs), and serotonin-
norepinephrine reuptake inhibitors (SNRIs). A new field of research involving Cannabis may 
be the link to the treatment of depression. However, studies show conflicting data as to 
whether cannabis is beneficial (Grinsponn & Balkar, 1998) or detrimental for the treatment of 
depression (Bovassa, 2001). Due to the conflicting results of these studies, Witkin switched 
the focus to the role of the endocannabinoid system and the treatment of depression from 
exogenously administered cannabinoids (Witkin et al., 2005). Since 2005, it has been 
concluded that the endocannabinoid system does play a role in the treatment of depression, 
but differs from minor depression to major depression. 
New research has found that a common characteristic of Cannabis, mood elevation, may be the 
link to the treatment of depression. A study published by El-Alfy and co-investigators in 2010 
describes the antidepressant effects associated with administration of phytocannabinoids. The 
objective of this study was to isolate the major cannabinoids from Cannabis and evaluate the 
antidepressant effects using the mouse forced swim test (FST), followed by the tail suspension 
test (TST). Typically in mice, when cannabinoids are administered they exert hypothermia and 
catalepsy, which means that a psychoactive state is being achieved. For these depression 
studies, only low dosages of these phytocannabinoids were administered so that the test 
subjects did not demonstrate psychoactive effects. The cannabinoids isolated and tested were 
cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC), cannabidiol (CBD), delta-8-
THC, and delta-9-THC (THC) (Figure 12).  
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Fig. 11. Chemical structure of the tricyclic antidepressant, Amitriptyline. 
 
         
Fig. 12. The six phytocannabinoids tested for antidepressant-like effects (El-Alfy et al., 2010). 
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To assess that hypothermia and catalepsy were not achieved, the tetrad assay was 
completed after administration of each cannabinoid. Out of the six cannabinoids tested, only 
delta-8-THC and delta-9-THC showed a U-shaped dose response in the forced swim test. 
With this, only delta-9-THC showed significant antidepressant-like effects. Administration 
of the non-psychoactive components revealed that CBC and CBD displayed antidepressant-
like effects in the forced swim test. However, a high dose of CBD was used to display these 
antidepressant-like effects.  
 
  
Fig. 13. Effects of each phytocannabinoid on immobility time in the mouse forced swim test 
(El-Alfy et al., 2010). 
To further confirm these tests, delta-9-THC and CBC were evaluated in the tail suspension 
test. Between these two phytocannabinoids, only delta-9-THC continued to exhibit these 
antidepressant-like effects at low doses. Therefore, the results of this study show that delta-
9-THC and other phytocannabinoids administered exogenously do indeed aid with the 
treatment of depression (El-Alfy et al., 2010). 
9. Phytocannabinoids and appetite stimulation 
Patients suffering from AIDS are now becoming the main target for the therapeutic use of 
Cannabis. Those with AIDS tend to lose their desire to eat regularly throughout the day. When 
this occurs, the patient becomes weak, agitated, tired, and anorexic; this occurrence in known 
as Wasting Syndrome. Research shows that at least 90% of patients who smoked marijuana 
had the desire to eat immediately after use (Haines & Green, 1970). With the use of Cannabis as 
a therapeutic drug to stimulate appetite, the suffering patients may be able to eat on a regular 
basis throughout the day, thus improving their quality of life. Several studies have shown that 
the use of marijuana does increase appetite, which also increases energy in daily life routines. 
In a study conducted by Mattes and colleagues, the appetite stimulating effects of 
cannabinoids, specifically THC, were examined. A major focus in this study, for a means of 
clarification from previous research, was the route of administration of THC. The four  
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Fig. 14. Effects of THC and CBC on immobility time in the mouse tail suspension test (El-
Alfy et al., 2010). 
different ways in which THC was administered includes oral, inhaled, sublingual, and 
suppository. There are high levels of variability in determining if THC does actually 
stimulate appetite. Factors such as environment, age, gender, tolerance, dosage, and social 
influences play a role in the effect of THC on appetite. During one study, the suppository 
route of administration resulted in the highest energy intake when compared to oral, 
sublingual, and inhaled administration of THC (Figure 15).  
 
Fig. 15. Mean data from patients dosed orally and via suppository over a 72 hour time 
period (Mattes et al., 1994). 
There is no single outcome on the effect of THC on appetite stimulation no matter the form 
of administration. The results vary from having no effect to the possibility of having major 
food cravings. In some circumstances, not only did the food cravings become increased, but 
during a meal the food seemed to also have an increased taste of delightfulness. The 
conclusion of this study indicates that THC as an appetite stimulant produces its highest 
effects on healthy, adult individuals who use low dosage amounts (Mattes et al., 1994). 
10. Future directions 
The growing population is becoming more aware of Cannabis as a medicinal plant, and not 
only a recreational drug. The first Cannabis publications date back to the early 1940’s in 
which there was only one publication from 1940-1949. Today, when a search is performed 
there are over 7,000 journal articles that discuss anything associated with the words 
Cannabis, cannabinoids, or endocannabinoids. Over the last 50 years, marijuana has become 
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the most widely used illegal drug, along with one of the most widely studied plants. There 
are still many questions to be answered within the Cannabis field of study. 
It is possible that the cannabinoid system has several other receptors that may explain the 
mechanism of action of compounds that exhibit cannabinoid-like effects when there is little 
or no affinity for CB1 or CB2. GPR55 and GPR119, both G-protein coupled receptors, are said 
to be novel cannabinoid receptors. All cannabinoid receptor antagonists appear to act as 
inverse agonists instead of neutral antagonists. There are few ligands starting to appear in 
literature as being neutral antagonists. Interest in this area could is important to help 
develop pharmacological tools to aid in finding neutral antagonists. These findings may 
possess unknown therapeutic advantages over receptor antagonists that act as inverse 
agonists (Pertwee, 2005).  
It is now known that phytocannabinoids interact with the CB1 and CB2 receptors, and that 
the human body consists of an endocannabinoid system that activates these two receptors. 
However, what these receptors look like remains a mystery. A general structure-activity 
relationship has been determined for the cannabinoids, but there is no limitation to 
synthesizing new compounds that will interact strongly with these receptors. In vitro and in 
vivo bioassays play a crucial role in determining the affinities and functions of compounds 
associated with the CB1 and CB2 receptors. The information determined from these 
bioassays will continue to help develop novel therapeutic drugs that potentially have 
pharmacological effects related to Cannabis without the deleterious side effects.  
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